Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
HDL-associated paraoxonase type 1 (PON1) can protect LDL and HDL against oxidative modification in vitro and therefore may protect against cardiovascular disease. We investigated the effects of PON1 levels, activity, and genetic variation on high density lipoprotein-cholesterol (HDL-C) levels, circu...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2005-03-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520340281 |
id |
doaj-196cd4817bef461aa3c81373da2dc325 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Thomas M. van Himbergen Mark Roest Jacqueline de Graaf Eugène H.J.M. Jansen Hiroaki Hattori John J.P. Kastelein Hieronymus A.M. Voorbij Anton F.H. Stalenhoef Lambertus J.H. van Tits |
spellingShingle |
Thomas M. van Himbergen Mark Roest Jacqueline de Graaf Eugène H.J.M. Jansen Hiroaki Hattori John J.P. Kastelein Hieronymus A.M. Voorbij Anton F.H. Stalenhoef Lambertus J.H. van Tits Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia Journal of Lipid Research atherosclerosis antioxidants polymorphisms |
author_facet |
Thomas M. van Himbergen Mark Roest Jacqueline de Graaf Eugène H.J.M. Jansen Hiroaki Hattori John J.P. Kastelein Hieronymus A.M. Voorbij Anton F.H. Stalenhoef Lambertus J.H. van Tits |
author_sort |
Thomas M. van Himbergen |
title |
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia |
title_short |
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia |
title_full |
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia |
title_fullStr |
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia |
title_full_unstemmed |
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia |
title_sort |
indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
2005-03-01 |
description |
HDL-associated paraoxonase type 1 (PON1) can protect LDL and HDL against oxidative modification in vitro and therefore may protect against cardiovascular disease. We investigated the effects of PON1 levels, activity, and genetic variation on high density lipoprotein-cholesterol (HDL-C) levels, circulating oxidized LDL (OxLDL), subclinical inflammation [high-sensitive C-reactive protein (Hs-CRP)], and carotid atherosclerosis. PON1 genotypes (L55M, Q192R, −107C/T, −162A/G, −824G/A, and −907G/C) were determined in 302 patients with familial hypercholesterolemia. PON1 activity was monitored by the hydrolysis rate of paraoxon, diazoxon, and phenyl acetate. PON1 levels, OxLDL, and Hs-CRP were determined using an immunoassay. The genetic variants of PON1 that were associated with high levels and activity of the enzyme were associated with higher HDL-C levels (P values for trend: 0.008, 0.020, 0.042, and 0.037 for L55M, Q192R, −107C/T, and −907G/C, respectively). In addition to the PON1 genotype, there was also a positive correlation between PON1 levels and activity and HDL-C (PON1 levels: r = 0.37, P < 0.001; paraoxonase activity: r = 0.23, P = 0.01; diazoxonase activity: r = 0.29, P < 0.001; arylesterase activity: r = 0.19, P = 0.03).Our observations support the hypothesis that both PON1 levels and activity preserve HDL-C in plasma. |
topic |
atherosclerosis antioxidants polymorphisms |
url |
http://www.sciencedirect.com/science/article/pii/S0022227520340281 |
work_keys_str_mv |
AT thomasmvanhimbergen indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia AT markroest indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia AT jacquelinedegraaf indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia AT eugenehjmjansen indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia AT hiroakihattori indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia AT johnjpkastelein indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia AT hieronymusamvoorbij indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia AT antonfhstalenhoef indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia AT lambertusjhvantits indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia |
_version_ |
1721506425457344512 |
spelling |
doaj-196cd4817bef461aa3c81373da2dc3252021-04-27T04:46:26ZengElsevierJournal of Lipid Research0022-22752005-03-01463445451Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemiaThomas M. van Himbergen0Mark Roest1Jacqueline de Graaf2Eugène H.J.M. Jansen3Hiroaki Hattori4John J.P. Kastelein5Hieronymus A.M. Voorbij6Anton F.H. Stalenhoef7Lambertus J.H. van Tits8Research Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsHDL-associated paraoxonase type 1 (PON1) can protect LDL and HDL against oxidative modification in vitro and therefore may protect against cardiovascular disease. We investigated the effects of PON1 levels, activity, and genetic variation on high density lipoprotein-cholesterol (HDL-C) levels, circulating oxidized LDL (OxLDL), subclinical inflammation [high-sensitive C-reactive protein (Hs-CRP)], and carotid atherosclerosis. PON1 genotypes (L55M, Q192R, −107C/T, −162A/G, −824G/A, and −907G/C) were determined in 302 patients with familial hypercholesterolemia. PON1 activity was monitored by the hydrolysis rate of paraoxon, diazoxon, and phenyl acetate. PON1 levels, OxLDL, and Hs-CRP were determined using an immunoassay. The genetic variants of PON1 that were associated with high levels and activity of the enzyme were associated with higher HDL-C levels (P values for trend: 0.008, 0.020, 0.042, and 0.037 for L55M, Q192R, −107C/T, and −907G/C, respectively). In addition to the PON1 genotype, there was also a positive correlation between PON1 levels and activity and HDL-C (PON1 levels: r = 0.37, P < 0.001; paraoxonase activity: r = 0.23, P = 0.01; diazoxonase activity: r = 0.29, P < 0.001; arylesterase activity: r = 0.19, P = 0.03).Our observations support the hypothesis that both PON1 levels and activity preserve HDL-C in plasma.http://www.sciencedirect.com/science/article/pii/S0022227520340281atherosclerosisantioxidantspolymorphisms |